Notification
No new Notification messages
Enviro Infra Engineers IPO is Open!
Apply for the Enviro Infra Engineers IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Dr. Reddy’s Laboratories Q2 Results FY24-25 Highlights, Revenue and PAT Analysis

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Dr. Reddy’s Laboratories delivered a strong Q2 FY24-25, showcasing substantial revenue growth with consolidated revenue reaching ₹80,162 million. However, profit after tax saw a slight decline. Explore detailed insights and segment breakdown.

Key Highlights

  • Revenue: ₹80,162 million, up 17% YoY
  • Profit After Tax (PAT): ₹13,415 million, down 9% YoY
  • EBITDA: ₹22,803 million, showcasing a resilient operational performance
  • EPS: Basic earnings per share at ₹15.07 for Q2 FY24-25

DR. REDDY S LABORATORIES

Trade

1209.3-5.14 (-0.42 %)

Updated - 25 November 2024
1247.00day high
DAY HIGH
1205.75day low
DAY LOW
3280431
VOLUME (BSE)

Quarterly - Dr. Reddy's Q2 Results FY24-25

Dr. Reddy’s Laboratories reported consolidated revenue of ₹80,162 million for Q2 FY24-25, a year-over-year increase of 17% and a quarter-over-quarter growth of 4%. Despite higher costs, the gross profit margin remained strong, supporting Dr. Reddy's growth across its generics and emerging markets segments.

The net profit after tax reached ₹13,415 million, a 9% decline YoY, mainly due to one-time expenses, including acquisition-related costs and tax adjustments. This stable financial performance, combined with strategic investments in research and partnerships, underscores Dr. Reddy’s ongoing commitment to operational efficiency and expansion into emerging markets.

Segment Highlights

  1. Global Generics: Revenue from the Global Generics segment was ₹71,576 million, reflecting a 17% YoY growth, mainly driven by increased sales volumes and new product launches.
  2. Pharmaceutical Services and Active Ingredients (PSAI): This segment delivered revenue of ₹8,407 million, boosted by higher volumes and an enhanced product mix.
  3. Others: The 'Others' segment contributed ₹179 million, indicating a drop from the previous year due to strategic focus on core areas.

Sector Expectations for Dr. Reddy's Q2 Results FY24-25

Dr. Reddy’s Q2 results exceeded industry expectations, with a substantial increase in revenue from its generics segment, especially in North America and emerging markets. This growth aligns with the sector’s robust demand for generic drugs, while slight declines in profit were anticipated due to higher SG&A and R&D investments.

Management Commentary

G V Prasad, Co-Chairman & MD of Dr. Reddy’s, noted, "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell® and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation."

Financial Table:

Metric

Q2 FY24-25

Q1 FY24-25

Q2 FY23-24

Revenue (₹ million)

80,162

76,727

68,802

Gross Profit (₹ million)

47,769

46,344

40,368

EBITDA (₹ million)

22,803

21,599

21,813

PAT (₹ million)

13,415

13,920

14,800

EPS (₹)

15.07

16.72

17.80

Selling & Administrative Expenses

23,007

22,691

18,795

R&D Expenses (₹ million)

7,271

6,193

5,447

Check out Dr Reddy's Lab's past performances in previous quarters and financial years.

Conclusion

Dr. Reddy’s Q2 results for FY24-25 demonstrate a solid performance with significant revenue growth across core segments. Despite challenges from rising costs and tax adjustments, the company has maintained a stable profit margin, underscoring its resilience and strategic focus. With new acquisitions, partnerships, and a strong presence in emerging markets, Dr. Reddy’s is well-positioned for sustained growth in the coming quarters.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text